ASBMR 2019 Presentations

11 FOP Presentations Will Be Made At The Annual Meeting

Each year, the American Society of Bone & Mineral Research (ASBMR) holds a scientific meeting for researchers to present their latest findings in bone research. More than 3,000 scientists from around the world attend this important research meeting.

This year, at the 2019 ASBMR Annual Meeting, FOP clinical trials are featured in a Rare Bone Disease Working Group Meeting. There will also be 11 presentations related to FOP! We would like to congratulate the researchers who had their abstract or presentation accepted by the ASBMR, see below. The 2019 ASBMR meeting will be held in Orlando, Florida, USA, September 20 to 23.

Robyn Allen
University of Pennsylvania, United States
Multiple modalities of signaling by FOP mutant BMP receptor in the developing zebrafish

Keith Babbs, PhD 
Keros Therapeutics, United States
Effects of daily palovarotene versus KTI-2338 administration on skeletal development in wild-type mice

Esmée Botman, PhD 
VU Medical Center, The Netherlands
18F-NaF PET/CT in forty-four patients with fibrodysplasia ossificans progressiva uncovers highly-prevalent, multifocal, metabolically-active heterotopic ossification, largely disassociated from flare-ups

Nanditha Das
Regeneron Pharmaceuticals, United States
Inhibition of Activin A does not ameliorate the formation of trauma-induced heterotopic ossification

Alison Davis
Blueprint Medicines, United States
A clinical update on BLU-782, an investigational selective ALK2 inhibitor in development for fibrodysplasia ossificans progressiva (FOP)

Sarah Hatsell, PhD 
Regeneron Pharmaceuticals, United States
The fibrodysplasia ossificans progressiva-causing ACVR1[R206H] and ACVR1[R258G] mutations exhibit distinct skeletal phenotypes in neonatal mice

Mai Kuratani 
Saitama University, Japan
Identification of a critical amino acid residue in ALK2 for the binding and inhibition by the anti-ALK2 blocking antibody

Ton Schoenmaker, BSc
Academic Centre for Dentistry Amsterdam, The Netherlands
Activin-A induces fewer, but larger, osteoclasts from CD14+ monocytes in both healthy controls and fibrodysplasia ossificans progressiva patients

Alexandra Stanley 
University of Pennsylvania, United States
Aberrant muscle tissue repair by mutant ACVR1 FOP progenitor cells

Amy Ton, MD
University of California, San Francisco, United States
Sensory neuron dysfunction underlies ACVR1-mediated pain in human heterotopic ossification

Chengzhu Zhao
Kyoto University, Japan
Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva models by an mTOR signaling modulator

Rare Bone Disease Working Group
On Friday, September 20, a Rare Bone Disease Working Group was held which featured a section on Rare Bone Disease Clinical Trial Updates. Three of the four trials featured FOP:

Maurizio Pacifici, PhD
University of Pennsylvania, United States
Fibrodysplasia ossificans progressiva and multiple hereditary exostoses

Eduardo Forleo Neto, MD, MSc
Regeneron Pharmaceuticals, United States
Fibrodysplasia ossificans progressiva

Tim LaBranche, DVM, PhD
Blueprint Medicines, United States
Fibrodysplasia ossificans progressiva

Make a Difference

Donate Connect Fundraise

Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter